The patients first since 30 years
For nearly 30 years this CHUM Gynecologic-Oncologist and researcher at the Institut du cancer de Montréal has been weaving a closer link between clinical work and fundamental research in order to better fight this cancer.
During her residency in Obstetrics and Gynecology at McGill University (1979-1984), Dr. Diane Provencher desired to better help her patients. Heading south to continue her training she began a postdoctoral position in Gynecologic Oncology at the University of Miami in 1986 and became "the second woman to join this American program!".
As a clinician, one thing was obvious to her: "the need to bridge the gap between clinical work and fundamental research in order advance the treatments that are offered to our patients."
Today, expertise developed at the Centre de Recherche du Centre Hospitalier de l’Université de Montréal (CRCHUM) resonates throughout a recent international study conducted by Dr. Diane Provencher via the Canadian Cancer Trials Group (CCTG): Study of Phase II Intraperitoneal Chemotherapy (IP) Combined with Intravenous (IV) Chemotherapy Versus IV Carboplatin and Paclitaxel Combination in Patients With Optimally Optimized Ovarian Epithelioma Surgery following neoadjuvant intravenous chemotherapy OV.21.
To read the rest of the article, click on the link.